西班牙15年经验:儿童心室辅助装置治疗的短期与长期生存
该观察性队列研究纳入2006年5月至2020年12月西班牙6个儿童心脏移植中心所有18岁以下首次植入心室辅助装置(VAD)的儿童,回顾性识别118例。67%存活至VAD撤除,64.9%存活至出院;非中枢神经系统出血(39%)和卒中(38.1%)最常见。体重<5 kg、先天性心脏病、植入前胆红素>34 μmol/l和桥接至决策策略与出院及长期死亡率较高相关。
要点
- 西班牙儿童VAD队列中67%存活至VAD撤除,64.9%存活至出院。
- 非中枢神经系统出血(39%)和卒中(38.1%)是最常见并发症。
- 体重<5 kg、先心病、胆红素>34 μmol/l、桥接至决策与出院及长期死亡相关。
核心结论
- 在西班牙,67%的VAD支持儿童已桥接至心脏移植或恢复。
- 体重低于5 kg、先天性心脏病诊断、胆汁淤积性肝功能障碍、桥接至决策作为VAD策略、INTERMACS-1状态和心脏骤停是与死亡率相关的植入前变量,而植入前肾脏替代治疗和体外膜氧合与死亡率无关。
研究设计与样本
- 观察性队列研究,纳入2006年5月至2020年12月在西班牙6个儿童心脏移植中心所有18岁以下首次植入VAD的儿童,从各医院数据库回顾性识别。
主要发现
- 118例儿童植入体外VAD,其中搏动型63%、连续型30.5%、两种类型5.9%。
- 小儿童(体表面积<0.7 m²)占队列的63.3%。
- 总体67%存活至VAD撤除,64.9%存活至出院。
- 非中枢神经系统出血(39%)和卒中(38.1%)是最常见并发症。
- 体重<5 kg、先天性心脏病、植入前胆红素>34 μmol/l和桥接至决策策略与出院时及长期死亡率较高相关;INTERMACS状态1和VAD植入前心脏骤停与长期死亡率相关;植入前肾脏替代治疗和体外膜氧合与死亡率无关。
关键数值与推荐
- 体重<5 kg、先天性心脏病、植入前胆红素>34 μmol/l、桥接至决策策略与出院时和长期死亡率较高相关。
- INTERMACS状态1和VAD植入前心脏骤停与长期死亡率相关。
- 植入前肾脏替代治疗和体外膜氧合与死亡率无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the use of ventricular assist devices (VAD) in children in Spain and to identify variables related to survival. METHODS: This is an observational cohort study of all children younger than 18 years of age who underwent an initial implantation of a VAD at any of the 6 paediatric heart transplant centres from May 2006 to December 2020. Subjects were identified retrospectively from each hospital's database. RESULTS: Paracorporeal VADs were implanted in 118 children [pulsatile (63%), continuous (30.5%) or both types (5.9%)]. Small children (<0.7 m2 of body surface area) comprised the majority of this cohort (63.3%). Overall, 67% survived to VAD explantation, and 64.9% survived to hospital discharge. Non-central nervous system haemorrhage (39%) and stroke (38.1%) were the most common complications. Body weight <5 kg, congenital heart disease, pre-implantation bilirubin >34 μmol/l and bridge to decision strategy were associated with a higher mortality at hospital discharge and in the long-term. Interagency registry for mechanically assisted circulatory support (INTERMACS) status 1 and cardiac arrest prior to VAD implantation were related to long-term mortality, whereas pre-implantation renal replacement therapy and extracorporeal membrane oxygenation were not related to mortality. CONCLUSIONS: In Spain, 67% of the VAD-supported children have been bridged to heart transplantation or to recovery. Body weight lower than 5 kg, congenital heart disease diagnosis, cholestatic liver dysfunction, bridge to decision as VAD strategy, INTERMACS-1 status and cardiac arrest were pre-implantation variables related to mortality, whereas pre-implantation renal replacement therapy and extracorporeal membrane oxygenation were not.
引用
- Menéndez JJ, Sánchez-Galindo AC, Balcells J, et al. Short- and long-term survival of children treated with ventricular assist devices in Spain, based on 15 years' experience. Eur J Cardiothorac Surg. 2023. PMID: 36759938. doi:10.1093/ejcts/ezad050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。